mutLBSgeneDB

mutLBSgeneDB
mutated Ligand Binding Site gene DataBase

Home

Download

 Statistics

Help

About Us

Bioinformatics and Systems Medicine Laboratory Bioinformatics and Systems Medicine Laboratory

Gene Summary

Ligand Binding Site Mutation Information

Protein Structure Related Information

Gene Expression and Gene-Gene Network

Phenotype Information

Pharmacological Information

Conservation Information for LBS

Gene summary for KLK6
Gene summary
Basic gene Info.Gene symbolKLK6
Gene namekallikrein-related peptidase 6
SynonymsBssp|Klk7|PRSS18|PRSS9|SP59|hK6
CytomapUCSC genome browser: 19q13.3
Type of geneprotein-coding
RefGenesNM_001012964.1,
NM_001012965.1,NM_002774.3,NM_001012966.1,
Descriptionkallikrein-6neurosinprotease Mserine protease 18serine protease 9zyme
Modification date20141207
dbXrefs MIM : 602652
HGNC : HGNC
Ensembl : ENSG00000167755
HPRD : 04037
Vega : OTTHUMG00000183098
ProteinUniProt: Q92876
go to UniProt's Cross Reference DB Table
ExpressionCleanEX: HS_KLK6
BioGPS: 5653
PathwayNCI Pathway Interaction Database: KLK6
KEGG: KLK6
REACTOME: KLK6
Pathway Commons: KLK6
ContextiHOP: KLK6
ligand binding site mutation search in PubMed: KLK6
UCL Cancer Institute: KLK6
Assigned class in mutLBSgeneDBB: This gene belongs to targetable_mutLBSgenes.

Gene ontology having evidence of Inferred from Direct Assay (IDA) from Entrez
GO IDGO TermPubMed ID
GO:0045745positive regulation of G-protein coupled receptor protein signaling pathway16885167


Top
Ligand binding site mutations for KLK6
Lollipop-style diagram of mutations at LBS in amino-acid sequence.
We represented ligand binding site mutations only. (You can see big image via clicking.)
 
: non-synonymous mutation on LBS, Circle size denotes number of samples.

Cancer type specific mutLBS sorted by frequency
LBSAAchange of nsSNVCancer type# samples
V211G209DKIRC1
H62A61GLUSC1
C218,I216P217HLUSC1
F151P152SSKCM1
L45H44RUCEC1
cf) Cancer type abbreviation. BLCA: Bladder urothelial carcinoma, BRCA: Breast invasive carcinoma, CESC: Cervical squamous cell carcinoma and endocervical adenocarcinoma, COAD: Colon adenocarcinoma, GBM: Glioblastoma multiforme, LGG: Brain lower grade glioma, HNSC: Head and neck squamous cell carcinoma, KICH: Kidney chromophobe, KIRC: Kidney renal clear cell carcinoma, KIRP: Kidney renal papillary cell carcinoma, LAML: Acute myeloid leukemia, LUAD: Lung adenocarcinoma, LUSC: Lung squamous cell carcinoma, OV: Ovarian serous cystadenocarcinoma, PAAD: Pancreatic adenocarcinoma, PRAD: Prostate adenocarcinoma, SKCM: Skin cutaneous melanoma, STAD: Stomach adenocarcinoma, THCA: Thyroid carcinoma, UCEC: Uterine corpus endometrial carcinoma.


Top
Protein structure related information for KLK6
Relative protein structure stability change (ΔΔE) using Mupro 1.1
Mupro score denotes assessment of the effect of mutations on thermodynamic stability.
  (ΔΔE<0: mutation decreases stability, ΔΔE>0: mutation increases stability)
: nsSNV at non-LBS: nsSNV at LBS

nsSNVs sorted by the relative stability change of protein structure by each mutation
Blue: mutations of positive stability change. and red : the most recurrent mutation for this gene.
LBSAAchange of nsSNVRelative stability change
F151P152S-1.7197944
H62A61G-1.6386328
I216P217H-1.5822956
C218P217H-1.5822956
V211G209D-0.80880333
L45H44R-0.5478289
(MuPro1.1: Jianlin Cheng et al., Prediction of Protein Stability Changes for Single-Site Mutations Using Support Vector Machines, PROTEINS: Structure, Function, and Bioinformatics. 2006, 62:1125-1132)

Structure image for KLK6 from PDB

Top
Differential gene expression and gene-gene network for KLK6
Differential gene expression between mutated and non-mutated LBS samples in all 16 major cancer types

Differential co-expressed gene network based on protein-protein interaction data (CePIN)
* Left PPI network was created from samples with mutations in the LBS of KLK6 and the right PPI network was created from samples without mutations in the LBS of KLK6. Only genes with p-value < 0.05 are shown.
Red circle: input gene. Orange circle: LBSgene. Blue circle: other gene.


Top

Top
Phenotype information for KLK6
Gene level disease information (DisGeNet)
Disease IDDisease name# PubMedAssociation type

Mutation level pathogenic information (ClinVar annotation)
Allele IDAA changeClinical significanceOriginPhenotype IDs

Top
Pharmacological information for KLK6
Gene expression profile of anticancer drug treated cell-lines (CCLE)
Heatmap showing the correlation between gene expression and drug response across all the cell-lines. We chose the top 20 among 138 drugs.We used Pearson's correlation coefficient.

Gene-centered drug-gene interaction network
Drug information targeting mutLBSgene (Approved drugs only)
Drug statusDrugBank IDNameTypeDrug structure
ExperimentalDB03127BenzamidineSmall molecule

Gene-centered ligand-gene interaction network

Ligands binding to mutated ligand binding site of KLK6 go to BioLip
Ligand IDLigand short nameLigand long namePDB IDPDB namemutLBS
0HL4-{[(3R)-3-{[(7-METHOXYNAPHTHALEN-2-YL) SULFONYL](THIOPHEN-3-YLMETHYL)AMINO}-2-OXOPYRROLIDIN- 1-YL]METHYL}THIOPHENE-2-CARBOXIMIDAMIDE3vfeAF151


Top
Conservation information for LBS of KLK6
Multiple alignments for Q92876 in multiple species
LBSAA sequence# speciesSpecies


Copyright © 2016-Present - The University of Texas Health Science Center at Houston
Site Policies | State of Texas